Halobet F Cream is a topical medication formulated with Halobetasol propionate (0.05% w/w), a potent corticosteroid, and Fusidic Acid (2% w/w), a bacteriostatic antibiotic. This combination is indicated for the treatment of inflammatory dermatoses complicated by bacterial infections, such as infected eczema, psoriasis, and other corticosteroid-responsive dermatoses with secondary bacterial involvement. Halobetasol exerts strong anti-inflammatory, antipruritic, and vasoconstrictive effects by modulating the immune response and inhibiting inflammatory mediators, thereby reducing redness, swelling, and itching. Fusidic Acid targets gram-positive bacteria, particularly Staphylococcus aureus, by inhibiting bacterial protein synthesis, effectively controlling and preventing secondary infections. Halobet F Cream is intended for topical application on affected skin areas, ensuring localized action with minimal systemic absorption. It should be used under medical supervision, typically applied in a thin layer once or twice daily for a limited duration to avoid potential corticosteroid-related adverse effects such as skin atrophy, telangiectasia, or hypothalamic-pituitary-adrenal axis suppression. Contraindications include viral, fungal, or tubercular skin infections. Patients should avoid contact with eyes and mucous membranes. Halobet F Cream offers an effective therapeutic option for managing inflammatory skin conditions complicated by bacterial infections, combining anti-inflammatory and antibacterial properties in a single formulation.